Cell News and Research

RSS

Lipid molecule fuels cancer growth

Cancer cells seldom start off stealthy. Quite to the contrary, they announce their presence to the immune system by planting chemical red flags right on their membranes. Once alerted, the body's defenses can swoop in, destroying rogue cells before they can do much damage. Lying at the heart of this early warning system are lipids, fatty compounds previously seen by cancer biologists primarily as a fuel source for burgeoning tumors.

18 Sep 2024

New insights into the mechanisms of efavirenz-induced neurotoxicity

Efavirenz is an important drug for treating HIV infection, but it has negative effects that can significantly impact patients' quality of life over time. It causes neuropsychiatric disorders and neurocognitive impairment in roughly 50 percent of patients. The drug is associated with abnormal lipid levels in blood plasma, but the molecular mechanisms responsible for negative clinical observations are unknown.

18 Sep 2024

A novel approach to biomolecule engineering

Thanks to a serendipitous discovery and a lot of painstaking work, scientists can now build biohybrid molecules that combine the homing powers of DNA with the broad functional repertoire of proteins - without having to synthesize them one by one, researchers report in a new study. Using a naturally occurring process, laboratories can harness the existing molecule-building capacities of bacteria to generate vast libraries of potentially therapeutic DNA-protein hybrid molecules.

18 Sep 2024

Mechanically stimulated 3D multicellular systems

To study biomechanical forces in multicellular systems, effective mechanical stimulation is an essential tool. A 3D microstructure device is developed using Two-Photon Polymerization (2PP)-based 3D printing for mimicking the human multicellular environment.

From Nanoscribe GmbH & Co. KG 18 Sep 2024

Long COVID patients maintain robust immune memory two years after infection

Researchers discovered that SARS-CoV-2-specific T and B cells in long COVID patients are maintained for two years, similar to fully recovered individuals, offering insights into long-term immunity.

17 Sep 2024

Innovative triplet therapy shows encouraging results in advanced chronic myeloid leukemia

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) – including both accelerated or myeloid blast phases of the disease – or Philadelphia chromosome-positive acute myeloid leukemia (AML) achieved a bone marrow remission when treated with a novel combination of decitabine, venetoclax and ponatinib.

17 Sep 2024

Lupus Research Alliance announces 2024 Diversity in Lupus Research Award recipients

The Lupus Research Alliance (LRA) is pleased to announce the recipients of the 2024 Career Development and Postdoctoral Awards to Promote Diversity in Lupus Research.

17 Sep 2024

IgM antibodies identified as critical for fighting S. aureus infections

Staphylococcus aureus, mostly known from its antibiotic-resistant variant Methicillin-resistant Staphylococcus aureus (MRSA), is among the leading causes of both community- and hospital-acquired infections.

17 Sep 2024

LJI breakthrough offers hope for universal antiviral against filoviruses

At this moment, the world has few tools to combat deadly filoviruses, such as Ebola and Marburg viruses. The only approved vaccine and antibody treatments protect against just one filovirus species.

17 Sep 2024

Activation of PPARβ/δ-AMPK pathway shown to slow liver fibrosis development

A study led by Manuel Vázquez Carrera, group leader at the Diabetes and Associated Metabolic Diseases Networking Biomedical Research Centre (CIBERDEM) at the University of Barcelona, reveals advances in the understanding and treatment of liver fibrosis, a serious complication in the context of metabolic fatty liver disease, also known as MASLD (metabolic dysfunction-associated steatotic liver disease).

17 Sep 2024

Ohio State's novel DHODH inhibitor enters first human trials

A new therapeutic agent discovered and developed at The Ohio State University will soon be used for cancer treatment at the patient's bedside as part of a clinical trial.

17 Sep 2024

$4.1 million funding supports epilepsy treatment research using spider venom proteins

UQ researchers have received $4.1 million from the Medical Research Future Fund to advance their research into epilepsy treatments made from spider venom proteins.

17 Sep 2024

The Key Role of iPSC-Derived Microglia in Research and Drug Discovery

Dr. Tilman explains the functions of iPSC-derived microglia and their relevance to conditions like Alzheimer’s.

From Axol Bioscience Ltd 17 Sep 2024

Newcells Biotech launches high-content and high-throughput imaging suite to advance pre-clinical drug development programmes

Newcells Biotech (“Newcells”), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, today announced the launch of its imaging suite and advanced lung Fibroblast-to-Myofibroblast Transition (FMT) assay.

From Newcells Biotech 17 Sep 2024

How nutrition and telomere dynamics shape beauty and aging in women

Research explores the intricate relationship between health, beauty, and aging in women, emphasizing the critical roles of telomere dynamics and nutrition in promoting longevity and vitality.

17 Sep 2024

Cell rejuvenation atlas unveils master regulators of rejuvenation strategies

A new research paper was published on the cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 17 on September 9, 2024, entitled, "The cell rejuvenation atlas: leveraging network biology to identify master regulators of rejuvenation strategies."

16 Sep 2024

Monoclonal antibodies could help provide an answer to antimicrobial resistance

Monoclonal antibodies – treatments developed by cloning a cell that makes an antibody – could help provide an answer to the growing problem of antimicrobial resistance, say scientists.

16 Sep 2024

ESMO 2024: Promising results in immunotherapy and antibody drug conjugates for gynecological cancers

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found 'promising' antitumor activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers.

16 Sep 2024

Brain-inspired materials pave the way for efficient computing

A team of researchers from Texas A&M University, Sandia National Lab - Livermore, and Stanford University are taking lessons from the brain to design materials for more efficient computing.

16 Sep 2024